Drug intelligence / Profile preview

MOD-001

Development stage: Preclinical
Lead developer: Modulo Bio
Modality: Small Molecules

Overview

MOD-001 is a preclinical small molecule developed by Modulo Bio. It targets the CSF1R receptor to reprogram microglia and reduce neuroinflammation, aiming to treat neurodegenerative diseases such as Frontotemporal Dementia (FTD) and Amyotrophic Lateral Sclerosis (ALS). The Alzheimer's Drug Discovery Foundation (ADDF) has provided a strategic investment to advance MOD-001 towards IND-enabling studies and first-in-human trials.

Targets

CSF1R (Macrophage colony-stimulating factor receptor)

Beyond the preview

Go deeper on MOD-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MOD-001.

Explore the full profile